Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody CetuximabKimio Yonesaka, Pasi A. Jänne, Dalia Ercan et al.|Science Translational Medicine|2011Cited by 670
B7-H3 Negatively Modulates CTL-Mediated Cancer ImmunityKimio Yonesaka, Kazuhiko Nakagawa, Koji Haratani et al.|Clinical Cancer Research|2018Cited by 169
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung CancerKimio Yonesaka, Kazuhiko Nakagawa, Junko Tanizaki et al.|Clinical Cancer Research|2021Cited by 92